Shannon Westin, MD

Shannon Westin, MD, MPH, FACOG, a gynecologic oncologist at The University of Texas MD Anderson Cancer Center, discusses the use of durvalumab with or without olaparib for the treatment of endometrial cancers.

The future of ovarian cancer treatment is discussed through a summary of current treatment options, future directions, and a review the unmet needs facing patients and physicians today.

Shannon Westin, MD, reviews essential treatment considerations for physicians when subscribing niraparib.

The utilization and effectiveness of using PARP inhibitors in treating ovarian cancer is considered.

Shannon Westin, MD, discusses niraparib and its relation to the design, efficacy, and practical implications of the PRIMA trial.

Systemic frontline therapy options are explored through the lens of treating ovarian cancer.

Shannon Westin, MD, analyzes the role of molecular testing in newly diagnosed ovarian cancer.

Shannon Westin, MD, discusses the prognosis of the case patient and the general prognosis and treatment options for ovarian cancer patients overall.

Shannon Westin, MD, introduces the case patient and highlights the diagnosis and treatment path to combat stage IV ovarian cancer.

Shannon Westin, MD, analyzes the diagnosis and treatment of a 68-year-old woman with recurrent ovarian cancer.